LMNL News and Press, Liminal Biosciences Inc From 07/21/22

Liminal BioSciences Announces Discontinuation of Fezagepras Development Canada NewsWire LAVAL, QC and CAMBRIDGE, England , July 21, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it h...

Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders Canada NewsWire LAVAL, QC and CAMBRIDGE, England , June 6, 2022 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Compa...

Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras PR Newswire LAVAL , QC and CAMBRIDGE, England , May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioScie...

Liminal BioSciences Inc. (LMNL) Q1 2022 Earnings Conference Call May 11, 2022 08:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participant...

The following slide deck was published by Liminal BioSciences Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Liminal BioSciences Inc. 2022 Q1 - Results - Earnings Call Presentation

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights Canada NewsWire Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacok...

Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022 PR Newswire LAVAL, QC and CAMBRIDGE, ENGLAND , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announ...

Liminal Biosciences to Present at Upcoming Investor Conferences Canada NewsWire LAVAL, QC , and CAMBRIDGE, England , May 9, 2022 /CNW/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutic...

Liminal BioSciences press release (NASDAQ:LMNL): FY net income of $12.2M for the year ended December 31, 2021 compared to a net loss of $118.8M for the year ended December 31, 2020. Revenue of $0.64M (-11.1% Y/Y). Cash was $108.5M at December 31, 2021 while the Company's working capital, i.e....

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results Canada NewsWire Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger Rep...